{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:18:08Z","timestamp":1794107888882,"version":"4.8.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Burns"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.burns.2026.108143","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:35:55Z","timestamp":1783092955000},"page":"108143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Toxic epidermal necrolysis: Management in the ICU"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5865-4772","authenticated-orcid":false,"given":"Camille","family":"Windsor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0742-2348","authenticated-orcid":false,"given":"Antoine","family":"Gaillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-7096","authenticated-orcid":false,"given":"Saskia","family":"Ingen-Housz-Oro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4833-4320","authenticated-orcid":false,"given":"Nicolas","family":"de Prost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.burns.2026.108143_bib1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjd.18424","article-title":"Incidence of and mortality from epidermal necrolysis (Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis) in France during 2003\u201316: a four-source capture\u2013recapture estimate","volume":"182","author":"Chaby","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib2","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.burns.2026.108143_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.burns.2026.108143_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00228-018-2569-3","article-title":"Incidence of Stevens-Johnson syndrome\/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study","volume":"75","author":"Rodr\u00edguez-Mart\u00edn","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.burns.2026.108143_bib5","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson Syndrome\/Toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib6","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaad.2020.10.091","article-title":"Changing spectrum of suspected drugs of epidermal necrolysis: A World Health Organization pharmacovigilance database analysis from 1997-2020","volume":"85","author":"Bettuzzi","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib7","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"R. Genetic Susceptibility to Toxic Epidermal Necrolysis","volume":"123","author":"Huynh","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jaad.2014.06.026","article-title":"Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review","volume":"72","author":"Canavan","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bjd.20775","article-title":"Lupus erythematosus and epidermal necrolysis: a case series of 16 patients","volume":"186","author":"Gaudin","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib10","article-title":"Recurrent reactive infectious mucocutaneous eruption in a male adult patient associated with Mycoplasma pneumoniae, SARS-CoV-2 and rhinovirus","volume":"16","author":"Dam","year":"2023","journal-title":"BMJ Case Rep CP"},{"key":"10.1016\/j.burns.2026.108143_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib12","first-page":"247","article-title":"Trends in mortality rates for Stevens-Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017","volume":"182","author":"Bettuzzi","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jdin.2023.06.014","article-title":"Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome","volume":"13","author":"Wasuwanich","year":"2023","journal-title":"JAAD Int"},{"key":"10.1016\/j.burns.2026.108143_bib14","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13023-018-0793-7","article-title":"Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins)","volume":"13","author":"Ingen-Housz-Oro","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.burns.2026.108143_bib16","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1111\/all.15889","article-title":"Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper","volume":"78","author":"Jutel","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.burns.2026.108143_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","article-title":"Severe cutaneous adverse reactions","volume":"10","author":"Hung","year":"2024","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.burns.2026.108143_bib18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.burns.2026.108143_bib19","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.burns.2026.108143_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/biomedicines11010177","article-title":"Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators","volume":"11","author":"Chu","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.burns.2026.108143_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-4362.1985.tb05749.x","article-title":"Clues to pathogenesis of toxic epidermal necrolysis","volume":"24","author":"Merot","year":"1985","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000069961","article-title":"Factor-XIIIa-positive dendrocytes in drug-induced toxic epidermal necrolysis (Lyell\u2019s syndrome): paradoxical activation in skin and rarefaction in lymph nodes","volume":"206","author":"Paquet","year":"2003","journal-title":"Dermatol Basel Switz"},{"key":"10.1016\/j.burns.2026.108143_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2133.1985.tb02356.x","article-title":"Involvement of macrophages in the pathology of toxic epidermal necrolysis","volume":"113","author":"Roujeau","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/archderm.1992.01680110060006","article-title":"J. Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases","volume":"128","author":"Roujeau","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00130832-200108000-00003","article-title":"Physiopathology and treatment of severe drug eruptions","volume":"1","author":"Bachot","year":"2001","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.burns.2026.108143_bib26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00000372-200010000-00005","article-title":"Immunoregulatory Effector Cells in Drug-Induced Toxic Epidermal Necrolysis","volume":"22","author":"Paquet","year":"2000","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.burns.2026.108143_bib27","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/bjd.19893","article-title":"Supportive care in the acute phase of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus","volume":"185","author":"Br\u00fcggen","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib28","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jaad.2020.02.066","article-title":"Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults","volume":"82","author":"Seminario-Vidal","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.annder.2024.103282","article-title":"French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis)","volume":"151","author":"Ingen-Housz-Oro","year":"2024","journal-title":"Ann Dermatol V\u00e9N\u00e9R\u00e9ologie"},{"key":"10.1016\/j.burns.2026.108143_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MD.0b013e3181ca4290","article-title":"Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures","volume":"89","author":"de Prost","year":"2010","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.burns.2026.108143_bib31","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00005792-200211000-00007","article-title":"A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters: implications for preventive strategies","volume":"81","author":"Safdar","year":"2002","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.burns.2026.108143_bib33","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/BCR.0b013e3181848bb1","article-title":"Toxic epidermal necrolysis clinical guidelines","volume":"29","author":"Endorf","year":"2008","journal-title":"J Burn Care Res Publ Am Burn Assoc"},{"key":"10.1016\/j.burns.2026.108143_bib34","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib35","article-title":"Chlorhexidine bathing of the critically ill for the prevention of hospital-acquired infection","volume":"8","author":"Lewis","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.burns.2026.108143_bib36","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1111\/jdv.16884","article-title":"Carrying out local care for epidermal necrolysis: survey of practices","volume":"35","author":"Ingen-Housz-Oro","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.burns.2026.108143_bib37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MD.0b013e3181ca4290","article-title":"Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures","volume":"89","author":"de Prost","year":"2010","journal-title":"Medicine"},{"key":"10.1016\/j.burns.2026.108143_bib38","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jaad.2019.03.030","article-title":"Incidence of bloodstream infections and predictive value of qualitative and quantitative skin cultures of patients with overlap syndrome or toxic epidermal necrolysis: A retrospective observational cohort study of 98 cases","volume":"81","author":"Lecadet","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/bjd\/ljae252","article-title":"Candidaemia and Candida colonization in patients with epidermal necrolysis: a retrospective case series","volume":"191","author":"Chantelot","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jinf.2017.03.011","article-title":"ICU-acquired candidaemia in France: Epidemiology and temporal trends, 2004-2013 - A study from the REA-RAISIN network","volume":"75","author":"Baldesi","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.burns.2026.108143_bib41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jama.281.3.261","article-title":"Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis","volume":"281","author":"Veenstra","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.burns.2026.108143_bib42","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/CCM.0b013e3181958915","article-title":"The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: a systematic review","volume":"37","author":"Hockenhull","year":"2009","journal-title":"Crit Care Med"},{"issue":"25","key":"10.1016\/j.burns.2026.108143_bib43","article-title":"Diagnosing and Managing Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Adults: Review of Evidence 2017-2023","author":"Ingen-Housz-Oro","year":"2025","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.burns.2026.108143_bib44","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/bjd.17428","article-title":"Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case series","volume":"180","author":"Gendreau","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib45","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00000658-199604000-00009","article-title":"Effect of ambient temperature on metabolic rate after thermal injury","volume":"223","author":"Kelemen","year":"1996","journal-title":"Ann Surg"},{"key":"10.1016\/j.burns.2026.108143_bib46","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/bjd.14934","article-title":"Renal replacement therapy during Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a retrospective observational study of 238 patients","volume":"176","author":"Papo","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib47","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00005373-197101000-00003","article-title":"Hemodynamic changes in the early postburn patient the influence of fluid administration and of a vasodilator (hydralazine)","volume":"11","author":"Pruitt","year":"1971","journal-title":"J Trauma Acute Care Surg"},{"key":"10.1016\/j.burns.2026.108143_bib48","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.clnu.2023.07.011","article-title":"ESPEN practical and partially revised guideline: Clinical nutrition in the intensive care unit","volume":"42","author":"Singer","year":"2023","journal-title":"Clin Nutr"},{"key":"10.1016\/j.burns.2026.108143_bib49","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/bjd.17267","article-title":"Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients","volume":"180","author":"Hefez","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib50","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib51","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/bjd.15360","article-title":"Long-term complications of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN): the spectrum of chronic problems in patients who survive an episode of SJS\/TEN necessitates multidisciplinary follow-up","volume":"177","author":"Lee","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib52","first-page":"E15","article-title":"Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis","volume":"101","author":"Woolridge","year":"2018","journal-title":"Cutis"},{"key":"10.1016\/j.burns.2026.108143_bib53","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.burns.2026.108143_bib54","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1684\/ejd.2020.3883","article-title":"A new case series on etanercept treatment for toxic epidermal necrolysis","volume":"30","author":"Paradisi","year":"2020","journal-title":"Eur J Dermatol EJD"},{"key":"10.1016\/j.burns.2026.108143_bib55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/09546634.2019.1577548","article-title":"Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review","volume":"31","author":"Zhang","year":"2020","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.burns.2026.108143_bib56","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamadermatol.2021.3154","article-title":"Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Insights From a Pan-European Multicenter Study","volume":"157","author":"Kridin","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib57","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis","volume":"84","author":"Tsai","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib58","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jaad.2022.01.039","article-title":"Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis in a cohort of patients","volume":"86","author":"Ao","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib59","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.anai.2022.05.009","article-title":"Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"129","author":"Tian","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.burns.2026.108143_bib60","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.jid.2018.03.1496","article-title":"Selective Use of Cyclosporine for Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis May Exclude Patients with Poor Prognostic Factors","volume":"138","author":"Noe","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.burns.2026.108143_bib61","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","author":"Jacobsen","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.burns.2026.108143_bib62","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.burns.2021.11.004","article-title":"Impact of multiple medical interventions on mortality, length of hospital stay and reepithelialization time in Toxic Epidermal Necrolysis, Steven-Johnsons Syndrome, and TEN\/SJS Overlap \u2013 Metanalysis and metaregression of observational studies","volume":"48","author":"Krajewski","year":"2022","journal-title":"Burns"},{"key":"10.1016\/j.burns.2026.108143_bib63","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41586-024-08061-0","article-title":"Spatial proteomics identifies JAKi as treatment for a lethal skin disease","volume":"635","author":"Nordmann","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.burns.2026.108143_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1421684","article-title":"Tumor necrosis factor inhibitors enhance corticosteroid therapy for\u00a0Stevens-Johnson\u00a0syndrome\u00a0and\u00a0toxic\u00a0epidermal\u00a0necrolysis\u00a0linked to immune checkpoint inhibitors: a prospective study","volume":"15","author":"He","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.burns.2026.108143_bib65","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.burns.2026.108143_bib66","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2018.06.002","article-title":"Minimal clinically important differences for measures of treatment efficacy in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"79","author":"Kim","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib67","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.0906-6705.2006.00426.x","article-title":"Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis","volume":"15","author":"Paquet","year":"2006","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib68","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.intimp.2005.11.012","article-title":"Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding","volume":"6","author":"French","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.burns.2026.108143_bib69","first-page":"329","article-title":"Severe cutaneous adverse reactions due to inappropriate medication use","volume":"179","author":"Chaby","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib70","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jid.2017.12.034","article-title":"Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients-Exposed\/Unexposed and Propensity Score-Matched Analyses","volume":"138","author":"Poizeau","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib71","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1365-2133.2006.07635.x","article-title":"Ciclosporin use in toxic epidermal necrolysis","volume":"156","author":"Danby","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib72","unstructured":"Pentoxyfylline in toxic epidermal necrolysis and Stevens-Johnson syndrome. Read QxMD n.d. \u3008https:\/\/read.qxmd.com\/read\/10583942\/pentoxyfylline-in-toxic-epidermal-necrolysis-and-stevens-johnson-syndrome\u3009."},{"key":"10.1016\/j.burns.2026.108143_bib73","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00007611-199610000-00015","article-title":"Cyclophosphamide in the treatment of toxic epidermal necrolysis","volume":"89","author":"Frangogiannis","year":"1996","journal-title":"South Med J"},{"key":"10.1016\/j.burns.2026.108143_bib74","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2133.1996.tb01167.x","article-title":"Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis","volume":"135","author":"Goulden","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib75","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000048174","article-title":"Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients","volume":"127","author":"Inamo","year":"2002","journal-title":"Three case Rep Int Arch Allergy Immunol"},{"key":"10.1016\/j.burns.2026.108143_bib76","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1001\/jama.1987.03390160093035","article-title":"Burn Treatment for the Unburned","volume":"257","author":"Pruitt","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.burns.2026.108143_bib77","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/bjd.18294","article-title":"Individual- and hospital-level factors associated with epidermal necrolysis mortality: a nationwide multilevel study, France, 2012\u20132016","volume":"182","author":"Traikia","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib78","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/bjd.15615","article-title":"Mortality of necrotizing fasciitis: relative influence of individual and hospital-level factors, a nationwide multilevel study, France, 2007-12","volume":"177","author":"Audureau","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib79","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13023-020-01538-x","article-title":"Management of ocular involvement in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: french national audit of practices, literature review, and consensus agreement","volume":"15","author":"Thorel","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.burns.2026.108143_bib80","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamadermatol.2014.4844","article-title":"Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Ear, Nose, and Throat Description at Acute Stage and After Remission","volume":"151","author":"Bequignon","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib81","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13023-023-02631-7","article-title":"Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus","volume":"18","author":"Ingen-Housz-Oro","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.burns.2026.108143_bib82","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ajo.2009.07.006","article-title":"Vision-Related Function After Scleral Lens Fitting in Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis","volume":"148","author":"Tougeron-Brousseau","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.burns.2026.108143_bib83","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bjd.14799","article-title":"Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"175","author":"Dodiuk-Gad","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib84","first-page":"153","article-title":"Vulvovaginal sequelae in toxic epidermal necrolysis","volume":"42","author":"Meneux","year":"1997","journal-title":"J Reprod Med"},{"key":"10.1016\/j.burns.2026.108143_bib85","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjd.13505","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission","volume":"172","author":"Duong","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2026.108143_bib86","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1346-8138.2006.00142.x","article-title":"Chronic pulmonary complications associated with toxic epidermal necrolysis: Report of a severe case with anti-Ro\/SS-A and a review of the published work","volume":"33","author":"Kamada","year":"2006","journal-title":"J Dermatol"}],"container-title":["Burns"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417926002950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417926002950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:06:51Z","timestamp":1790366811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305417926002950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":86,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0305417926002950"],"URL":"https:\/\/doi.org\/10.1016\/j.burns.2026.108143","relation":{},"ISSN":["0305-4179"],"issn-type":[{"value":"0305-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxic epidermal necrolysis: Management in the ICU","name":"articletitle","label":"Article Title"},{"value":"Burns","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.burns.2026.108143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108143"}}